Regulation of adoptive immunotherapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells represents a significant advancement in treating hematological malignancies.
• CAR-T cell therapy, particularly CD19 CAR-T, is anticipated for early clinical use in B cell malignancies in Japan.
• Development of novel CAR-T therapies for non-B cell malignancies is also expected.

Purpose of the Study:

• To summarize the regulatory landscape for adoptive immunotherapy in Japan.
• To explain the implications of key Japanese legislation on CAR-T cell therapy development.

Main Methods:

• Review of the "Act on the Safety of Regenerative Medicine" (2014).
• Review of the "Revised Pharmaceutical Affairs Act" (2014).
• Analysis of how these Acts enable clinical research and market launch of CAR-T products.

Main Results:

• The Act on the Safety of Regenerative Medicine permits "specified cell products" for clinical research.
• The Revised Pharmaceutical Affairs Act allows "regenerated medical products" for clinical trials and market entry.
• These regulations are crucial for advancing CAR-T therapy in Japan.

Conclusions:

• Japanese regulations provide a framework for the development and clinical application of CAR-T cell therapy.
• The established legal pathways are essential for introducing innovative treatments like CAR-T therapy for hematological cancers.